Annovis Bio (ANVS) Cash from Financing Activities (2019 - 2026)

Annovis Bio has reported Cash from Financing Activities for 8 years, with the latest figure at $3.7 million in Q1 2026.

• Quarterly Cash from Financing Activities fell 81.31% year-over-year to $3.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.5 million (down 55.98% YoY) and the FY2025 annual result came in at $34.6 million, up 29.63% from the prior year.
• Cash from Financing Activities slipped to $3.7 million in Q1 2026 per ANVS's latest filing, from $13.2 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $19.8 million in Q1 2025 and troughed at $4613.0 in Q1 2022.
• A 5-year average of $6.9 million and a median of $5.3 million in 2024 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities jumped 59675.25% in 2024, then slumped 86.12% in 2025.
• Over 5 years, Cash from Financing Activities stood at $4613.0 in 2022, then soared by 189901.17% to $8.8 million in 2023, then slipped by 29.25% to $6.2 million in 2024, then surged by 112.45% to $13.2 million in 2025, then plunged by 71.92% to $3.7 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $3.7 million, $13.2 million, and $1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.